Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

RESI JPM San Francisco 2023 Program Guide

5 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

DF-News-09142022

2023 kicks off Life Science Nation’s 10th Anniversary. This celebratory year begins with our first conference of the year, RESI JPM San Francisco, next week, January 10 in person and January 11-12 virtual! This hybrid conference will take place at the Marines’ Memorial Club & Hotel in San Francisco, and we are excited to release the digital RESI Program Guide. Check out the variety of panelists, exhibitors and workshops participating in this RESI. In addition, make sure to check out the Innovator’s Pitch Challenge, where over 50 companies will pitch to a panel of investor judges.

RESI-JPM-2023-Program-Guide_01052023-cover

We look forward to seeing you at RESI next week! You can still register for the conference and begin to book meetings in partnering today.

Register-now-button-new

RESI-SF-2023-Banner-1100-wide

Companies to Watch 2023

29 Dec

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

DF-News-09142022

For the past ten years, Life Science Nation (LSN) has built a global partnering platform that matches scientist-entrepreneurs and fundraising CEOs with capital, licensing and product collaboration partners. In that time, LSN has learned so much about what makes a compelling fit for our buyside partners. I have had discussions with hundreds of investors, and I always want to understand how their investment theme of seeking early-stage technology assets is balanced with the risk of going early. Unsurprisingly, it’s complicated, but it typically revolves around focusing on key attributes of the company, the science, the management team, key milestones already achieved, and the all-important data that supports that the technology is heading in the right direction.

Similarly, I have developed my own set of attributes that I personally look for when I meet the companies that are referred to me through LSN’s relationship with regional tech hubs, incubators, and accelerators or national government and state life science agencies. These are what I look for:

  • The Founding Scientist – Is there a scientist with a long lineage with the key science and the technology assets inside the company? A lot of the “new” technologies are actually the latest iteration of technologies that have been worked on for decades. When the scientist that is associated with that technology is still involved either as CTO, advisory or board compacity, that helps de-risk the opportunity. Having the world-renowned expert onboard and that thread of historical continuity provides not only perspective, but credence to the validation and the translating of the technology. Even if the assets are not that old, a thorough comprehension of the history, context, and potential to show future partners that the technology is in the hands of leadership with an appropriate understanding and appreciation of what it is capable of.
  • The CEO – There are a few categories of CEO that I see in many of these startups. Experience matters and which side of the house the startup CEO has been on in the past matters and will affect how the company addresses the challenges that will surface along the startup journey. Personally, I have an affinity for the CEOs who were mid-level executives in big drug or device companies, and who were responsible for managing and getting successful products out the door in the past. It is even better when one or more of those products was a blockbuster. This type of CEO that has been-there-done-that in a corporate play and now wants to take all that knowledge, expertise, and leverage it in a new startup. I then ask myself, “Can this CEO listen? Is he/she coachable with an ability to learn quickly and discern, accept, and apply sound feedback?”
  • Management Team – I like a diverse management team with similar experience as described above that augments and complements the CEO. A CEO should not surround themselves with a team that closely resembles their own strength and skillset. A savvy CEO will build a team with relevant experience and together possess expertise in how the game is played. They understand from past corporate experience when to hold them, when to fold them, and when to pivot. A diverse professional team that has seen success in the past and now wants to take their startup to the big leagues will generate traction and get their exit.
  • Milestones and Data – Show a cogent well-thought-out plan based on hitting realistic achievable milestones that will produce compelling, validating data to show that the product is on the right path and going in the right direction. CEOs and their teams gain credibility when they present this aspect honestly and correctly, and when they are not coordinated, they lose credibility, and thus a chance for partnerships. Having realistic milestones that will produce compelling validating data is crucial to partnering.
  • Entrepreneurial Agency – I have been talking about entrepreneurial agency for a while now. It’s hard to describe, but you know it when you see it. It’s the vibe you get, the confidence that is exuded, the passion, the professionalism, the unbridled desire, and determination. Entrepreneurial agency gives a company mojo which, in turn, creates positive propulsion forward. I mentioned that I like to see seasoned CEOs with experience in large enterprises that are now leading startups and taking their shot. However, there remain many seats at the table for the young, dynamic CEO that has followed their passion and their love for finding a scientific solution for an unmet medical need and wants to impact the healthcare arena. There are plenty of both types of CEOs in the early-stage arena, and that is driving this golden age of life science that we are all living in.

Keeping in mind the outline above, I would like to name my list of “Companies to Watch in 2023.”  I have been exposed to all these companies and have watched them as they have progressed and grown. I like where they are at and where they are headed. I have not done any scientific diligence or evaluated them for any other third-party entities. I have compiled this list to showcase these companies as potential up-and-comers in the life science arena for Next Phase newsletter readers and RESI Conference attendees. Companies to Watch in 2023… Drum roll please…

AVM Biotechnology is a clinical stage company advancing its small molecule, AVM0703, in a Phase I/II clinical trial in patients with relapsed/refractory (R/R) no-option Non-Hodgkin’s Lymphoma/Leukemia (NHL). Led by a strong executive leadership team and global scientific advisory board, the company is planning for accelerated FDA approval in Acute Lymphoblastic Leukemia (ALL), a patient subset of NHL, and a commercial launch in mid-2024. Additionally, preclinical data suggests potential applications in solid tumors and autoimmune diseases. AVM has been awarded three Phase I NIH Small Business Innovation Research grants by the National Cancer Institute (NCI) and National Institute of Diabetes and Kidney Disease (NIDDK) as well as two Phase II grants from the same agencies. The company holds eight worldwide patent families directed to AVM0703 and has developed a robust and proprietary patenting strategy resulting in granted claims and patent protection that should extend to 2040. In a single, one-hour outpatient infusion, AVM0703 rapidly induces, expands, and mobilizes endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells by a glucocorticoid-receptor-independent mechanism. Durable Clinical Response has been achieved in R/R NHL/Leukemia including T-cell Lymphoma to at least 9 months with favorable safety results. AVM0703 also potentiates chemotherapy and CAR-T response in pre-clinical models.


BaeRyeo Innovation is a Jeju company specializing in Nitric Oxide based ingredients. Incorporated in 2018, we have developed a unique technology where we created a revolutionary new substance which could protect, prevent and even restore stiff and hard blood vessels, the cause of cardiovascular diseases.

Nitric Oxide Synthase weakens as we age so the ability to produce Nitric Oxide in our body decreases. Nitric Oxide has been termed the “miracle molecule” because of the long list of benefits it brings to our body. This is why it has been widely studied by scientists worldwide, hoping to use it as a form of treatment.

Our product, the NODT (Nitric Oxide Donor Transporter) increases Nitric Oxide in the body. Pre-clinical tests have proven that blood vessels of hypertensive rats do not burst even under 100% pressure and this discovery can definitely help people suffering from atherosclerosis which leads to coronary heart diseases, the No. 1 killer in America.

We have several other pre-clinical tests that show outstanding improvements from hypertension, diabetes, enteritis and enhanced immunity – all these being possible when we have sufficient Nitric Oxide in the body.

Our joint research with America’s Nitric Oxide specialist Dr. Joseph Bauer from Walsh Univeristy will commence this September to proceed our studies further in proving the vast capabilities of Nitric Oxide can bring to the human race.


Based on the research results of Professor Sang Sun Yoon’s laboratory at Yonsei University College of Medicine, BioMe Inc. was established as a faculty start-up with the aim of developing Live Biotherapeutic Products derived from human microbiome.

Through research over the past 10 years, we have secured a number of “Active Human Beneficial Bacteria” whose therapeutic efficacy has been verified. We conducted research on the intestinal microbiome as well as the respiratory microbiome, and derived development pipelines for various indications including but not limited to inflammatory bowel disease, infectious disease, cardiovascular disease, colorectal cancer, and dyslipidemia. In addition, we have secured a number of isolates with new functions among the strains designated safe by the Ministry of Food and Drug Safety and are developing jointly with domestic and foreign pharmaceutical and food companies.

Establishment of symBioMecollectionTM: Possessing a symbiotic microbiome library according to various lifestyles and health conditions (Over 400 people’s stool and saliva). Source material for identification of new beneficial bacteria. Joint research and development with lead pharmaceutical companies in progress.


De Motu Cordis is a clinical stage company based in Australia. We have developed a needle-free drug device combination for the immediate treatment of anaphylaxis. We successfully completed our First in Human trial in 2022. Our dry powder inhaler has performed 8 times faster than EpiPen™ in the clinic, it is needle free, it does not have restrictive storage conditions, it will have a long shelf life and is about one third the size of an EpiPen™. We are on track to lodge our NDA in Q4 2024. This is the first product from our platform technology for rapid administration of drugs in emergency situations, when every second counts. We will open a Series A round of US $20m in mid-2023 to take our product through an efficacy trial and pivotal study. We are in RESI to engage with investors and strategic partners to accelerate our path to market.


glyPAQ is a workflow for simultaneous preparation of biological samples for structure-based glycan and proteomics analysis

Key Features:

  • glyPAQ enables quantitative MS-based glycan structure studies without requiring pre-purification of specific proteins or specialized expertise for sample preparation.

  • glyPAQ utilizes multiple internal standards for quality control of all sample handling steps and to normalize LC retention times and aid glycan structure assignment.

  • glyPAQ can be applied for routine glycomic profiling starting with just 1 μl serum or plasma, providing an innovative strategy to develop non-invasive biomarkers for precision medicine.

  • glyPAQ can be used to simultaneously prepare biological samples for structure-based glycomics and proteomics analysis.


Hemex Health has launched “Gazelle” — a new generation of point-of-care diagnostics. Gazelle platforms combine proprietary technology with mHealth advantages to reach new levels of test accuracy and economic value. Gazelle”s market success is demonstrated in its adoption by small labs, clinics, community hospitals and NGOs in 26 countries. Hemex tests are easy to use, robust for challenging environmental settings, and digitally connected. Gazelle includes: 1) the only miniaturized, automated electrophoresis test for hemoglobinopathy testing in 8 minutes and 2) an advanced fluorescent immunoassay (FIA) technology with superior detection over other leading platforms. These powerful technologies can support a large menu of tests. Gazelle is also being miniaturized further into a palm-sized device”targeted for the US home market and exploding mHealth market worldwide.


Moremmé is a female & black-owned, development stage therapeutics company dedicated to providing products that are hormone-free, scientifically designed, natural solutions to Genitourinary Syndrome of Menopause (GSM). GSM is a term coined to comprehensively describe the changes that occur in women’s vaginal and urogenital tract due to loss of estrogen. These include vaginal atrophy with symptoms of vaginal dryness, irritation, pain during sexual intercourse, lower urinary tract symptoms of urinary frequency, urgency and recurrent urinary tract infections.

Moremmé is the result of a labor of love of 3 passionate female scientists. We are dedicated to empowering women with body-positive suite of products that preserve and restore vaginal health.


NeuroAge Therapeutics is a longevity techbio company that creates FDA-approved drugs to rejuvenate the brain and treat neurodegenerative disorders including Alzheimer’s disease ($25B/yr global market). We will have earlier sources of revenue through first targeting rare neuro disorders through FDA fast track and a direct-to-consumer NeuroAge test. My team has more than 25 years of combined experience in this field from top institutions (MIT, U. Cambridge, UC Berkeley) and pharma companies (Sanofi). Here is a recent article in the Guardian that sets up the type of company that we are and the public appeal.


Suma is an online management system that simplifies and streamlines the licensing and renewal process for medical professionals. Initially, our product will target workers that have an increased labor market dropout risk yet are in high demand, highly diverse and have high care impact. Certified Nurse Assistants (CNA) and Home Health Aides (HHA) provide basic direct patient care, measure vitals and help patients with activities of daily living (ADL) such as feeding, grooming, bathing, etc. They work predominantly in nursing homes, home health agencies, hospitals, and other long-term care settings caring for the elderly, sick and/or disabled. These positions are held mostly by people of color, women, immigrants, low income and at-risk populations, and are considered entry-level nursing positions. There is an overwhelming need for these healthcare workers nationwide and creating an easy way to maintain their employment will provide resources for our economy and save businesses thousands of dollars every year.Suma is an online management system that simplifies and streamlines the licensing and renewal process for medical professionals. Initially, our product will target workers that have an increased labor market dropout risk yet are in high demand, highly diverse and have high care impact. Certified Nurse Assistants (CNA) and Home Health Aides (HHA) provide basic direct patient care, measure vitals and help patients with activities of daily living (ADL) such as feeding, grooming, bathing, etc. They work predominantly in nursing homes, home health agencies, hospitals, and other long-term care settings caring for the elderly, sick and/or disabled. These positions are held mostly by people of color, women, immigrants, low income and at-risk populations, and are considered entry-level nursing positions. There is an overwhelming need for these healthcare workers nationwide and creating an easy way to maintain their employment will provide resources for our economy and save businesses thousands of dollars every year.


High blood pressure is related to three of the leading causes of death in America: heart disease, stroke, and kidney disease. As of 2017, almost half of the American population (roughly 108 million) had high blood pressure. There is a lack of technology available to individuals for monitoring their blood pressure continously in a noninvasive and affordable way, and prevent the development of diseases related to high blood pressure. Our team hopes to address the issues with current blood pressure monitoring technologies and save millions of lives by integrating the Vena Vitals blood pressure sensor with a single-lead wrist based ECG device to calculate pulse transit time and provide continuous blood pressure data in real time.

Introducing IPC Pitch Judges at RESI JPM San Francisco

29 Dec

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

The Life Science Nation (LSN)‘s RESI JPM San Francisco 2023 is only less than two weeks away! For this conference, the Innovator’s Pitch Challenge (IPC) is especially popular and we are featuring over 50 presenting startups from across 14 sessions, each focusing on a specific sector/subsector. The LSN team has been very busy recruiting for active investors and industry experts to join the pitch judge panels. The investor and industry experts were invited to sessions based on their experience, investment interest and expertise. The judges will listen to 4-minutes of company pitches and have 8-9 minutes to engage in Q&A and provide feedback to the pitching companies.

Below is a partial list of IPC pitch judges at RESI San Francisco. Sign up for RESI SF 2023 to join them!


Brent Ahrens
General Partner
Canaan Partners

Ivneet Bhullar
Principal
Fusion Fund

Jian Cao
Sr Research Manager & Technical Fellow
Medtronic

Evan Caplan
Principal
OrbiMed Advisors LLC

Dipty Desai
Co-Chair, TiE Global Health
TiE Angels

Karen Drexler
Life Science Councils
Astia Angels

Gary Gershony
Partner
BayMed Venture Partners

Anton Gopka
CEO and General Partner
ATEM Capital

Linda Greub
General Partner
Avestria Ventures

Michael Hansen
Innovation Scouting Director – North America
Eppendorf

Dave Hood
West Coast Outreach
Medical Technology Enterprise Consortium (MTEC)

Melya Hughes Crameri
Managing Director
Awen GmbH

Tomoko Ishikura
Partner
Kicker Ventures

Elizabeth Kayser
Member
Barrington Angels

Moazam Khan
Business Advisor
Velocity Incubator

John Kim
Principal
Aphelion Capital, LLC

Kristin King
Member
Boston Harbor Angels

Bill Mantzoutsos
Angel Investor

Linda Maxwell
Director
Biomedical Zone

James Mayer
Senior Manager, Investment & Venture Services
Centre for Aging + Brain Health Innovation (CABHI)

Matthew McNamara
Chief Investment Officer
Horizon 3 Biotech

Brian Meshkin
Managing Partner
Profound Ventures

Ting Pau Oei
Venture Partner
Gore Range Capital

Daniel Parera
Partner
Kurma Partners

Diana Saraceni
Founder, Managing Director
Panakes Partners

Eran Steinberg
Imaging Arts

Lu Wang
Foothill Ventures

Kyoko Watanabe
Managing Director
DEFTA Partners

Tad Weems
Managing Director
Agilent Technologies

Travis Whitfill
Partner
Bios Partners

RESI-SF-2023-Banner-1100-wide

Partnering At RESI JPM San Francisco

29 Dec

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Partnering opened for RESI JPM San Francisco on December 19, and the RESI partnering platform is a hive of activity. The primary goal of RESI has always been to foster conversations between companies, investors and strategic partners, and service providers who can all work together to bring the next generation of healthcare technology to market. As a hybrid conference, we are seeing the number of meetings booked increase steadily. The hybrid format proves to be one that works for the RESI community, as we see meetings being scheduled for both the in-person conference and still seeing about half of the meetings so far scheduled virtually. For those who are still thinking of registering, there’s still time! You can still register for both in-person on Tuesday, January 10 at the Marines’ Memorial Club & Hotel (hurry, this is almost SOLD OUT), and Virtual January 11-12. In our experience, over 50% of the meetings are booked within the week before the conference, so there is still a lot of time left to book plenty of meetings!

RESI San Francisco is LSN’s largest event of the year – with over 400 investors already registered, and more registering every day, start the new year off right by catapulting your fundraising campaign forward with all the networking opportunities available at RESI and JPM.

RESI-SF-2023-Banner-1100-wide

Watershed Informatics Exhibit at RESI JPM San Francisco

15 Dec
Madeline-Kelly
Madeline Kelly
Interview with Madeline Kelly, Head of Sales, Watershed Informatics

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti
Caitlin Dolegowski

Watershed Informatics’ intuitive Data Lab platform empowers our clients to design, execute, and iterate their own sequencing analyses, shortening time between iterations and enabling more efficient and effective experimentation. They expedite and multiply the development of targeted, breakthrough therapies and diagnostics. Watershed returns to RESI this January as an exhibitor. In the following interview, Watershed’s Head of Sales, Madeline Kelly, provides insight on how Watershed came to be, their technology, team, and target customer.

Caiti Dolegowski (CD): Please introduce us to Watershed. Tell us about your technology and platform.

Madeline Kelly (MK): Watershed Informatics is the first fully verticalized bio-IT platform. Our Cloud Data Lab enables life sciences organizations of any size to perform mission-critical bioinformatics analyses (such as bulk, single-cell, and spatial transcriptomics; WGS, proteomics, protein folding, AI/ML etc.) at an order of magnitude less cost and complexity than existing solutions. With purpose-built infrastructure specifically optimized for catalyzing the life sciences development pipeline, our product enables biologists to analyze their own data and bioinformaticians to rapidly prototype and deploy bespoke analytic workflows across an organization.

CD: Tell us about Watershed’s team?

MK: We are a team of expert bioinformaticians, software engineers, and biologists inspired by one mission: to enable all scientists – regardless of their programming capabilities – to leverage multi-modal data for building better drugs faster.

CD: Watershed’s Cloud Data lab can be traced to a conversation between co-founders, Jonathan Wang and Mark Kalinich. What was the conversation and how do they complement each other?

MK: Jonathan and Mark have been friends since their first day of MIT – they were actually next-door neighbors freshman year! As a software engineer, Jonathan has always been fascinated by high-performance computational infrastructure. He co-founded an algorithmic trading firm while still a student at MIT. While there, he perfected the tech stack required to democratize access to petabyte-scale ML infrastructure for software engineers and financial researchers alike. Mark is a Harvard-trained physician-scientist with nearly 15 years of translational research experience across diagnostics and therapeutics development. His mission is to improve the lives of patients by developing and deploying the enabling technologies required to bring therapeutics out of the laboratory and into the clinic. Their expertise and passions directly intersect at the problem Watershed solves: uncorking the bottleneck for biotech and pharma’s data-intensive research efforts.

CD: Who is your target customer? And what are the different offerings you provide your clients?

MK: Our target customers want to successfully and efficiently analyze their big biology data (most often -omics, but also protein folding and high content imaging) without the massive overhead currently required. (To learn more about what we mean by overhead, download our white paper). With our no-code / low-code / high-code interoperability, our platform is useful to biologists and bioinformaticians alike.

CD: Do you have a process for assessing your clients’ needs? How does that work?

MK: Watershed employs a highly consultative sales and onboarding process. We thoroughly assess the needs of our customers by learning about their workflow, analysis, and visualization needs. Our team of bioinformaticians are ready to assist our clients from day 1.

CD: Could you give us examples of current Watershed clients and how they’ve utilized your informatics?

MK: Some of our clients include SalioGen, Cellino, SynDevRx, Rejuvenate Bio, Rarebase, Revitope, and a few stealth biotech startups. Our customers’ most common request is processing next-generation sequencing data across a variety of workflows (bulk, single-cell, and spatial RNAseq; whole genome and whole exome sequencing, bulk and single-cell ATACseq, immune repertoire sequencing, CRISPR-based analyses, custom sequencing libraries, etc) and technologies (Illumina, ONT, PacBio). In addition to other data-intensive workflows (metabolomics, proteomics, high-content imaging, protein-folding) and publicly available datasets (TCGA, CCLE, GTex, UKBB), our platform has been purpose-built to overlay advanced AI/ML techniques on these data, including deep learning, generative AI, structure-based learning models, and NLP, among others.

CD: We’re thrilled to Watershed back as an exhibitor at RESI JPM San Francisco! What would you like our RESI attendees to know about Watershed

MK: We are excited to join RESI JPM San Francisco as first-time attendees! We want to meet as many of you as possible, so swing by our booth to check out our platform and enter for a chance to win 1 free month of Watershed’s Cloud Data Lab (details available at the conference). See you there!

RESI-SF-2023-Banner-1100-wide

RESI JPM San Francisco 2023 Investor Panelists

15 Dec

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

RESI JPM San Francisco 2023 is fast approaching. The Life Science Nation (LSN) team has been busy putting together a program of 8 panels that provides latest insights on early-stage life science and healthcare.

We are excited to have invited a diverse lineup of panelists from different types of investment groups, including Big Pharma, corporate VCs, medtech strategics, traditional VCs, angels and family offices, to share their strategies and approaches on early-stage investment, perspectives on industry landscape, startup ecosystem and more. As a global conference, we are also delighted to have many international investors and cross-border investment groups to join and contribute to these dynamic discussions. The goal of RESI panels is to facilitate constructive conversations between investors and fundraising CEOs, and provide tactical advice on how companies can raise capital and acquire partnerships effectively. These must-see panels are great opportunities for founders and CEOs to engage with investors and kick off their fundraising journey of 2023.

Join the panelists below at RESI JPM San Francisco:


Mel Barsky
Director of Business Development
Centre for Aging + Brain Health Innovation (CABHI)

Lana Caron
Innovation Lead
Philips Ventures
Bruce Cohen
Bruce Cohen
Venture Partner
Xeraya Capital
Matt Deschner
Matt Deschner
Business Development & Licensing – Surgical Innovations
Medtronic

Gini Deshpande
Partner of Cathay Capital
Niels Emmerich
Niels Emmerich
Vice President, Global Head Search and Evaluation
AbbVie
Xi Fang
Xi Fang
Managing Partner
Button Capital
Jon Friedland
Jon Friedland
Managing Director, Ventures
Cleveland Clinic Ventures
Amit Garg
Amit Garg
Managing Partner
Tau Ventures
Lana Ghanem
Lana Ghanem
Managing Director
Hikma Ventures
Tom Gibbs
Tom Gibbs
Director
Debiopharm Innovation Fund
Gita Gupta
Gita Gupta
Partner
NextStep Ventures
Duncan Huston-Paterson
Duncan Huston-Paterson
Senior Manager, Business Development
Amgen
Kristin King
Kristin King
Member
Boston Harbor Angels
Fiona Mack
Fiona Mack
VP, Head of CoLaborator
Bayer
Nola Masterson
Nola Masterson
Managing Director
Science Futures
Andrew Meadow
Andrew Meadow
General Partner
Health Innovation Capital
Tamir Meiri
Tamir Meiri
Senior Manager, Venture Investments
Johnson & Johnson Innovation
Ole Mensching
Ole Mensching
Co-Founder and General Partner
Apollo Health Ventures
Ravi Mistry
Ravi Mistry
Angel Investor
John Parker
John Parker
Founder & Managing Director
Springhood Ventures
Armin Rump
Armin Rump
Manager, Global Business Development
Otsuka Pharmaceutical
Akhil Saklecha
Akhil Saklecha
Chief Scientific Officer, Acute Care
Danaher Corporation
Yoke Sin
Yoke Sin
Managing Partner
iGlobe Partners
Lesley Stolz
Lesley Stolz
Regional Vice President, Early Innovation Partnering
Johnson & Johnson Innovation
Sally Wang
Sally Wang
Venture Partner
Viva BioInnovator
Oscar Zhang
Oscar Zhang
Principal
Qiming Venture Partners
Lu Zhang
Lu Zhang
Managing Partner
Fusion Fund
Cheryl Zimberlin
Cheryl Zimberlin
Investment Director
M Ventures

RESI-SF-2023-Banner-1100-wide

Crafting the Perfect Message

15 Dec

By Karen Deyo, Director of Investor Research, Israel BD, LSN

You’ve registered for a partnering conference.

You’ve filled out a profile in the partnering system detailing who you are and what your company does.

You’ve researched the investors in attendance and built a list of targets to book meetings with.

You hit “Request a Meeting” and freeze.

What message will increase your chances of the investor accepting the request?

Partnering is an involved process with multiple steps that must be taken to ensure optimal results. These steps often require major time investment, and we forget that, even after the hours we’ve poured into the process, none of it matters without a compelling message to pique the interest of a potential partner. Furthermore, this is a process that requires a plan for following up, since, as with any outreach, it will likely take more than one message to the investors to receive a response. These messages should be clear and concise, no more than a paragraph, highlighting your company and what makes it unique.

Life Science Nation (LSN) has developed and consolidated your partnering outreach into four separate messages:

  1. Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
  2. Company tagline (5-6 words explaining who you are and what you do)
  3. Elevator pitch (1-3 sentences describing the company and tech)
  4. Technology differentiation, product innovation, or market position
  5. Raise and milestone information
  6. Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
  7. Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development? What makes your people special?
  8. Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later.

It should go without saying that the perfect message is meaningless without a well-researched and formulated target list and marketing collateral at the ready. Think of the perfect message like how an athlete approaches the arena on game day. It’s the starting shot of a long and exciting process. It won’t replace the training and conditioning that got you to game day, but it’ll ensure you’re off with a competitive edge.

Partnering opens December 19 for RESI JPM San Francisco (Jan 10 In Person & January 11-12 Virtual) and there is still time to register! Contact us to see which investors are currently active in our partnering system who may be a fit for you.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development, Entrepreneurial Education Lead
Book a Meeting
Email Me

RESI-SF-2023-Banner-1100-wide

%d bloggers like this: